226 related articles for article (PubMed ID: 37162605)
1. Metastasis prevention with bone-targeted agents: a complex interaction between the microenvironment and tumour biology.
Coleman R
J Bone Miner Metab; 2023 May; 41(3):290-300. PubMed ID: 37162605
[TBL] [Abstract][Full Text] [Related]
2. Bone-Targeted Agents and Metastasis Prevention.
Coleman R
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892899
[TBL] [Abstract][Full Text] [Related]
3. Anticancer activity of bisphosphonates in breast cancer.
Gnant M
Anticancer Agents Med Chem; 2012 Feb; 12(2):114-22. PubMed ID: 21864231
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
5. Clinical benefits of bone targeted agents in early breast cancer.
Coleman R
Breast; 2019 Nov; 48 Suppl 1():S92-S96. PubMed ID: 31839171
[TBL] [Abstract][Full Text] [Related]
6. Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates.
Wilson C; Holen I; Coleman RE
Cancer Treat Rev; 2012 Nov; 38(7):877-89. PubMed ID: 22398187
[TBL] [Abstract][Full Text] [Related]
7. The curability of breast cancer and the treatment of advanced disease.
Guarneri V; Conte PF
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
Hadji P; Coleman RE; Wilson C; Powles TJ; Clézardin P; Aapro M; Costa L; Body JJ; Markopoulos C; Santini D; Diel I; Di Leo A; Cameron D; Dodwell D; Smith I; Gnant M; Gray R; Harbeck N; Thurlimann B; Untch M; Cortes J; Martin M; Albert US; Conte PF; Ejlertsen B; Bergh J; Kaufmann M; Holen I
Ann Oncol; 2016 Mar; 27(3):379-90. PubMed ID: 26681681
[TBL] [Abstract][Full Text] [Related]
9. The endocrine influence on the bone microenvironment in early breast cancer.
Wilson C; Brown H; Holen I
Endocr Relat Cancer; 2016 Dec; 23(12):R567-R576. PubMed ID: 27687494
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
11. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
Lipton A
Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
Gaudio A; Xourafa A; Rapisarda R; Castellino P
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates in oncology.
Coleman RE; McCloskey EV
Bone; 2011 Jul; 49(1):71-6. PubMed ID: 21320652
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates: ready for use as adjuvant therapy of breast cancer?
Theriault RL
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):61-6. PubMed ID: 19934757
[TBL] [Abstract][Full Text] [Related]
15. The role of bisphosphonates in the adjuvant setting for breast cancer.
Reeder JG; Brufsky AM
Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
[TBL] [Abstract][Full Text] [Related]
16. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
Dhesy-Thind S; Fletcher GG; Blanchette PS; Clemons MJ; Dillmon MS; Frank ES; Gandhi S; Gupta R; Mates M; Moy B; Vandenberg T; Van Poznak CH
J Clin Oncol; 2017 Jun; 35(18):2062-2081. PubMed ID: 28618241
[TBL] [Abstract][Full Text] [Related]
17. The role of bisphosphonates as adjuvant therapy for breast cancer.
Gralow JR
Curr Oncol Rep; 2001 Nov; 3(6):506-15. PubMed ID: 11595119
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.
Strobl S; Wimmer K; Exner R; Devyatko Y; Bolliger M; Fitzal F; Gnant M
Curr Treat Options Oncol; 2018 Mar; 19(4):18. PubMed ID: 29527635
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy with bone-targeted agents.
Wilson C; Coleman RE
Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
